Investment Opportunity
Building a Platform to Enable Cytosolic Delivery in Oncology
Xelcis Bio™ is developing TRIDENT™, an enabling delivery platform designed to improve the probability of success for high-value oncology programs where cytosolic access is a critical barrier.
SCROLL
Investment Opportunity
Addressing a High-Value Bottleneck
Failure to achieve cytosolic delivery is a major source of attrition across multiple oncology modalities. By enabling functional intracellular activity, TRIDENT™ is positioned to unlock value across existing portfolios and emerging therapeutic classes.
Why Delivery Is the Opportunity
Many high-value oncology programs — including targeted protein degradation, RNA therapeutics, and intracellularly acting biologics — fail not because the biology is flawed, but because the payload does not reach its intracellular site of action. A platform that improves cytosolic delivery across modalities has broad leverage across oncology drug development.
Market Opportunity
Platform Leverage Across Large Markets
TRIDENT™ addresses delivery constraints across multiple therapeutic modalities, each representing a significant commercial opportunity.
$12B+
Targeted Protein Degradation
Targeted Protein Degradation \nPrimary near-term focus. PROTACs and molecular glues require cytosolic delivery to drive functional degradation.
$3B+
RNAi / Nucleic Acids
RNA therapeutics depend on intracellular delivery, and endosomal escape remains a central barrier to functional activity.
$3B+
Biologics and Nanobodies
nIntracellularly acting biologics face the same endosomal barrier. TRIDENT™ is designed to improve cytosolic delivery across payload formats.
$10B+
Targeted Chemotherapy
TDOX serves as an internal validation program, demonstrating TRIDENT™’s potential to improve intracellular exposure while reducing off-target burden.
Business Model
Partnership-Driven Growth
Xelcis is pursuing a capital-efficient strategy centered on platform licensing, target-specific partnerships, and selective internal development.
Platform Licensing
License TRIDENT™ delivery rights for defined targets or programs in exchange for upfront fees, R&D support, milestones, and royalties.
Target-Specific Partnerships
Collaborate around individual assets within partner portfolios, enabling rapid technical evaluation and efficient go/no-go decisions.
Selective Internal Development
Advance internal programs that validate the platform and create standalone strategic value.
Use of Funds
Data Generation to Enable Partnerships
Seed financing is focused on generating the data and manufacturing readiness needed to support pharma partnership discussions.
Platform Validation Across Modalities
Cross-modality expansion data — KRAS PROTAC, MYC PROTAC, molecular glue, PD-L1 nanobody — expected in 2026 to support partnership outreach.
Partner-Ready Data Packages
Structured data outputs designed for technical diligence — cellular uptake, functional activity, resistance models, and translational alignment endpoints.
Lead Program Advancement
Manufacturing readiness and TDOX validation data to support both partnership credibility and the path toward proprietary program advancement.
